# FDA Warning Letter: Novo Nordisk Inc.
> 2026-03-10 · Center for Drug Evaluation and Research (CDER) · `c1f71dde3caf0be1`
## Letter
- **Company:** Novo Nordisk Inc.
- **Posted Date:** 2026-03-10
- **Letter Issue Date:** 2026-03-05
- **Issuing Office:** Center for Drug Evaluation and Research (CDER)
## Subject
Postmarketing Adverse Drug Experience Reporting Requirements
---
*Source: [FDA Warning Letters](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters) · AI Analytics · CC0 1.0*